• Genome&Company bought back KRW 1.3 billion face value of its 1st unsecured private convertible bond before maturity on Oct. 7, 2026.
• Total purchase price was KRW 1.44 billion, including principal and interest, following bondholders’ put option exercise.
• The company plans to cancel the bonds, reducing the outstanding principal amount to zero.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genome&Company published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261007900356), on October 07, 2026, and is solely responsible for the information contained therein.